Status:
COMPLETED
Carvedilol Post-intervention Long-term Administration in Large-scale Trial
Lead Sponsor:
Takeshi Morimoto
Conditions:
Myocardial Infarction
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate whether beta-blocker therapy improves 6-year clinical outcomes in patients with ST-segment elevation acute myocardial infarction and preserved left ventricular...
Detailed Description
Beta-blocker therapy is recommended after ST-segment elevation acute myocardial infarction (STEMI) in the current guidelines although its efficacy in those patients who have undergone primary percutan...
Eligibility Criteria
Inclusion
- Patients with STEMI after primary PCI
- Patients with left ventricular ejection fraction more than or equal to 40%
Exclusion
- Patients with left ventricular ejection fraction less than 40%
- Patients with contraindication for beta-blocker
- Patients with implantable cardioverter defibrillators
- Patients with end-stage malignancy
Key Trial Info
Start Date :
July 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2017
Estimated Enrollment :
801 Patients enrolled
Trial Details
Trial ID
NCT01155635
Start Date
July 1 2010
End Date
March 1 2017
Last Update
June 27 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Division of Cardiology, Kyoto University Hospital
Kyoto, Japan, 606-8507